• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Morphic Holding Inc (NQ: MORF )

    56.99 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Morphic Holding Inc

    < Previous 1 2 3 4 5 Next >
    Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
    Upgrades 
    Via Benzinga
    Short Volatility Alert: Morphic Holding, Inc.
    On Thursday, shares of Morphic Holding, Inc. (NASDAQ: MORF) experienced volatile short activity. After the activity, the stock price went up +4.69% to $22.53. The overall... 
    Via Benzinga
    Looking Into Morphic Holding's Return On Capital Employed
    Benzinga Pro data, Morphic Holding (NASDAQ:MORF) reported Q1 sales of $2.38 million. Earnings fell to a loss of $31.48 million, resulting in a 47.11% decrease from last quarter. 
    Via Benzinga
    Morphic Holding: Q1 Earnings Insights
    Morphic Holding (NASDAQ:MORF) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    What 4 Analyst Ratings Have To Say About Morphic Holding
    Over the past 3 months, 4 analysts have published their opinion on Morphic Holding (NASDAQ:MORF) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
    Via Benzinga
    Wells Fargo Maintains Overweight Rating for Morphic Holding: Here's What You Need To Know
    Wells Fargo has decided to maintain its Overweight rating of Morphic Holding (NASDAQ:MORF) and lower its price target from $81.00 to $79.00. Shares of Morphic Holding are trading down 3.76% over the... 
    Via Benzinga
    71 Biggest Movers From Yesterday
    Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
    Via Benzinga
    Stocks Flounder As Wall Street Rotates Out Of Tech
    Big Tech stocks are struggling ahead of several key earnings reports. 
    Via Talk Markets
    34 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday... 
    Via Benzinga
    CFO And COO Of Morphic Holding Trades $2.2M In Company Stock
    Marc Schegerin, CFO And COO at Morphic Holding (NASDAQ:MORF), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A Form 4... 
    Via Benzinga
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    The Past Week's Notable Insider Buys Include AppLovin, Cricut, Biotechs, And More
    With earnings-reporting season all but over, many insiders are free once more to buy or sell shares. Here are a few of the most noteworthy insider purchases that were reported in the past week. 
    Via Talk Markets
    Stocks That Hit 52-Week Lows On Wednesday
    On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
    Upgrades 
    Via Benzinga
    The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More
    Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders were making return trips to the buy window... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
    Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
    Via Benzinga
    Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
    Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data... 
    Via Benzinga
    The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
    Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
    Via Talk Markets
    Exposures COVID-19 Product Safety
    The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
    Via Benzinga
    The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
    Via Benzinga
    Topics Product Recall
    Exposures COVID-19 Legal Product Safety
    The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
    Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
    Via Benzinga
    Exposures Product Safety
    Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, More
    Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near all-time highs. Some return buyers were among the insiders... 
    Via Benzinga
    Is Morphic Holding a Buy?
    This experimental biotech has more than tripled investors' money over the past 12 months. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.